“The study is further evidence that newer medicines are at prices which are affordable in the UK, and it acknowledges the difference between the often quoted ‘list price’ and the lower prices actually paid for medicines by the NHS." said David Watson, Director - Pricing and Reimbursement at ABPI.
"This suggests that the UK is getting a fair deal with regards to medicines pricing and that the NHS can be assured that it is getting good value for money".
"In addition the UK also has the benefit of a unique scheme where the pharmaceutical industry pays hundreds of millions of pounds back to the Government each year; money which is meant to go back into supporting the cost of medicines in the NHS.
"Despite this we know patients are still not getting access to some new and innovative medicines. The UK has poor outcomes for cancer care compared to some of these comparable countries. If we really want our hospitals here in the UK to provide World class cancer care, we need to invest and ensure our system can accelerate the use of clinically and cost effective medicines. Government has a key role to play in allowing this to happen."
Click here to view the Lancet report.